prior therapy

prior therapy

Any therapy given to a patient for a particular condition before starting a new regimen for managing the same condition. Prior therapy is of particular interest when enrolling a patient in a clinical study or trial.
References in periodicals archive ?
carfilzomib) in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Patients received three or more lines of prior therapy (median of five), including a PI and an IMiD.
The currently approved indications for IMBRUVICA are: 1) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, 2) for the treatment of CLL patients with del 17p, a genetic mutation that occurs when part of chromosome 17 has been lost, and 3) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Food and Drug Administration (FDA) approval for IMBRUVICA (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Today, the distinct tolerability profile of BOSULIF offers physicians an important therapeutic choice for their patients with Ph+ CML, as has already been shown in patients who are resistant or intolerant to prior therapy.
Clavis will continue to concentrate on elacytarabine and its Phase III study dubbed CLAVELA in patients with acute myeloid leukaemia (AML) who have failed prior therapy.
Sprycel is currently approved for treating adults with resistance or intolerance to prior therapy for chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
VELCADE (bortezomib) for Injection, the market leader for multiple myeloma and mantle cell lymphoma patients, who have received at least one prior therapy, is the first and only marketed proteasome inhibitor.
The FDA has approved Tykerb (lapatinib), in combination with Xeloda (capecitabine), for the treatment of women with advanced HER2-positive breast cancer who have received prior therapy.
GlaxoSmithKline recently announced that the FDA has approved TYKERB[R] (lapatinib), in combination with Xeloda[R] (capecitabine), for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
It was approved in June 2006 for the treatment of adults with chronic-phase, acute-phase, or myeloid or lymphoid blast-phase chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy, including imatinib, and for the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) with resistance to prior therapy.
Patients with low-grade non-Hodgkin's lymphoma who have not undergone prior therapy to treat the disease may be eligible for a Phase III vaccine study.